PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)
today issued an update regarding the second phase of its three phase, scorpion
venom-derived peptide research and development program. The program consists of
identifying, extracting and sequencing peptides and proteins isolated from
Caribbean Blue Scorpion venom. The goal of the program is to empower
PreveCeutical to produce Nature Identical™ peptide therapeutics to treat,
regulate and prevent cancer progression. The company’s initial focus will
target glioblastoma, a highly-aggressive form of brain cancer. PreveCeutical
has started phase 2 of the program, comprised of re-designing the peptides to
enhance their biostability while upholding their potency during screening
against well-characterized and defined targets associated with brain cancer.
The company’s research team employs advanced computer technology for its
in-silico modelling and docking studies against identified brain cancer targets
to determine critical structural features and amino acid sequences. Using its
proprietary peptide linker technology, PreveCeutical will begin to re-engineer
the identified peptides after they are generated from the modelling and docking
studies to conserve the structural features responsible for binding and other
critical activities. Each novel, uniquely designed Nature Identical™ peptide
candidate will then be purified, fully characterized and added to a wide-ranging
library of candidates. Upon completion of this phase, PreveCeutical will enter
phase 3 and begin screening the peptides in cell-based glioblastoma models.
To view the full press release, visit http://ibn.fm/KRCoU
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops
innovative options for preventive and curative therapies utilizing organic and
nature identical products. PreveCeutical aims to be a leader in preventive health
sciences and currently has five research and development programs, including:
dual gene therapy for curative and prevention therapies for diabetes and
obesity; the Program; Nature Identical™ peptides for treatment of various
ailments; non-addictive analgesic peptides as a replacement to the highly
addictive analgesics such as morphine, fentanyl and oxycodone; and a
therapeutic product for treating athletes who suffer from concussions (mild
traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster.
CELLB9® is an oral solution containing polarized and potentiated essential
minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion
venom. This product is available on the company’s website. For more information
about PreveCeutical, please visit www.PreveCeutical.com
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment